Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noac205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Shannon P Fortin Ensign und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, FDA HHS, U.S. Food and Drug Administration.
Abstract (Originalsprache)
Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical prognostic implications that are independent of histologic grading. The homozygous deletion of CDKN2A/B is the strongest implicated independent indicator of the poor prognosis within IDH-mutant astrocytoma, and the identification of this alteration in these lower histologic grade tumors transforms their biology toward an aggressive grade 4 phenotype clinically. CDKN2A/B homozygous deletion is now sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance, yet there are currently no effective molecularly informed targeted therapies for these tumors. The biological impact of CDKN2A/B homozygous deletion in IDH-mutant tumors and the optimal treatment strategy for this molecular subgroup remains insufficiently explored. Here we review the current understanding of the translational significance of homozygous deletion of CDKN2A/B gene expression in IDH-mutant astrocytoma and associated diagnostic and therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Caterina Giannini, Jann N Sarkaria, Evanthia Galanis, Sani H Kizilbash
Förderung
- NCI NIH HHS
- FDA HHS
- U.S. Food and Drug Administration
- National Cancer Institute
Zitieren
APA
Fortin Ensign, S. P., Jenkins, R. B., Giannini, C., Sarkaria, J. N., Galanis, E., & Kizilbash, S. H. (2023). Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac205
Vancouver
Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac205
BibTeX
@article{FortinEnsign2023,
author = {Fortin Ensign, Shannon P and Jenkins, Robert B and Giannini, Caterina and Sarkaria, Jann N and Galanis, Evanthia and Kizilbash, Sani H},
title = {Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noac205}
}
EUVIMED